Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q5VW36
UPID:
FOCAD_HUMAN
Alternative names:
-
Alternative UPACC:
Q5VW36; D3DRJ9; Q6ZME1; Q8IZG0; Q96JM8; Q96MS9; Q9BVF3; Q9NX87
Background:
Focadhesin plays a crucial role in maintaining proteostatic levels of SKIC2 and SKIC3 in the liver, indicating its significant involvement in cellular homeostasis. Additionally, it is implicated in the regulation of RNA degradation, showcasing its potential impact on gene expression and cellular function.
Therapeutic significance:
Given its association with severe congenital liver disease, focadhesin's study offers a promising avenue for developing targeted therapies aimed at mitigating hepatic dysfunction and improving patient outcomes.